INVION LIMITED — Director's Dealing 2011

Nov 24, 2011

Replacement Explanatory Memorandum CBio Limited ACN 094 730 417

25 November 2011

The Manager Company Announcements Office ASX Limited 20 Bridge St SYDNEY NSW 2000

Dear Sir

UPDATED APPENDICES 3Y – CHANGE OF DIRECTOR’S INTEREST NOTICE

Please find attached updated Appendices 3Y for Messrs Monsour, Brooks and Mangelsdorf.

Analytica Limited (‘Analytica’) has held shares and options in CBio Limited (‘CBio’) since it listed on ASX. Messrs Monsour, Brooks and Mangelsdorf are directors of Analytica and the shares and options held are not for the benefit of the three Directors.

However, with the recent appointments of Messrs Brooks and Mangelsdorf to the Board of CBio, it is considered prudent to update the Director’s Interest Notices to reflect the indirect interest of all three directors due to their positions held with Analytica.

ROSLYNN SHAND

Company Secretary

1

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity CBIO LIMITED ABN 76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the following the director for the purposes of section	information under listing rule 3.19A.2 and as agent for 205G of the Corporations Act.
Name of Director	ROSS MANGELSDORF
Date of last notice	17 October 2011

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect - described below
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ross Mangelsdorf Tambien Pty Ltd Tambien Pty Ltd Manowe Pty Ltd Rossdown Investments Pty Ltd Unit Trust> Mr Mangelsdorf is a director and beneficiary of the Super fund Analytica Limited – Mr Mangelsdorf is a Director
Date of change	3 November 2011
No. of securities held prior to change	Indirect: 1,666,994 ordinary shares and 150,000 Options exercisable at $1.00 each, expiry 31/12/2012
Class	Ordinary fully paid shares and Options
Number acquired	1,044,712 shares and 3,000,000 options exercisable at$1.00 each by31 Dec 2012
Number disposed	Nil

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non‐cash, provide details and estimated valuation	Shares – $500,000 Options - nil
No. of securities held after change	Indirect: 2,711,706 ordinary shares and 3,150,000 Options exercisable at $1.00 each, expiry 31/12/2012
Nature of change Example: on‐market trade, off‐market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy‐back	Directorship, appointment – indirect interest

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [433 x 341] intentionally omitted <==

----- Start of picture text -----

Detail of contract n/a
Nature of interest n/a
Name of registered n/a
holder
(if issued securities)
Date of change n/a
No. and class of n/a
securities to which
interest related prior
to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired n/a
Interest disposed n/a
Value/Consideration n/a
Note: If consideration is non‐cash, provide details
and an estimated valuation
Interest after change n/a
----- End of picture text -----

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 – [+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during thisperiod?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity          CBIO LIMITED
ABN                     76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the following the director for the purposes of section	information under listing rule 3.19A.2 and as agent for 205G of the Corporations Act.
Name of Director	DR MICHAEL MONSOUR
Date of last notice	17 October 2011

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct - Dr Michael Monsour Indirect-described below
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1. MP Monsour Medical Practice Pty Ltd Superannuation Fund A/C> 2. MPAMM Pty Ltd 3. Australian Biofunds Investments Limited Dr Monsour is a Director and shareholder of the entities identified above. Analytica Limited – Mr Monsour is a director
Date of change	3 November 2011

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change	1. Dr Michael Monsour 90,013 ordinary shares 2. MP Monsour Medical Practice Pty Ltd Superannuation\ Fund\ A/C> 2,502,922 ordinary shares and 1,490,000 share options 3. MPAMM Pty Ltd 9,377,956 ordinary shares, 1,614,000 share options & 200,000 Performance Rights 4. Australian Biofunds Investments Limited 194,280 ordinary shares
Class	Ordinary fully paid shares and Options
Number acquired	1,044,712 shares and 3,000,000 options exercisable at$1.00 each by31 Dec 2012
Number disposed	nil
Value/Consideration Note: If consideration is non‐cash, provide details and estimated valuation	Shares – $500,000 Options - nil
No. of securities held after change	1. Dr Michael Monsour 90,013 ordinary shares 2. MP Monsour Medical Practice Pty Ltd Superannuation\ Fund\ A/C> 2,502,922 ordinary shares and 1,490,000 share options 3. MPAMM Pty Ltd 9,377,956 ordinary shares, 1,614,000 share options & 200,000 Performance Rights 4. Australian Biofunds Investments Limited 194,280 ordinary shares 5. Analytica Limited – 1,044,712 ordinary shares and 3,000,000 options exercisable at $1.000 each by 31 Dec 2012
Nature of change Example: on‐market trade, off‐market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy‐back	Directorship, appointment – indirect interest

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non‐cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – [+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during thisperiod?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity          CBIO LIMITED
ABN                     76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	WARREN BROOKS
Date of last notice	10 November 2011

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect - described below
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	W Brooks Investments Pty Ltd fund> of which Mr Brooks is a director and beneficiary of the Super fund Analytica Limited–Mr Brooks is a director
Date of change	3 November 2011
No. of securities held prior to change	2,005,000 ordinary shares - direct and indirect
Class	Ordinary fully paid shares and Options
Number acquired	1,044,712 shares and 3,000,000 options exercisable at$1.00 each by31 Dec 2012
Number disposed	nil
Value/Consideration Note: If consideration is non‐cash, provide details and estimated valuation	Shares – cash, various Options - nil
No. of securities held after change	3,049,712 ordinary shares and 3,000,000 options exercisable at $1,00 each by 31 Dec2012

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Directorship, appointment – indirect interest Example: on‐market trade, off‐market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy‐back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non‐cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – [+] Closed period

Were the interests in the securities or No contracts detailed above traded during a + closed period where prior written clearance was required? If so, was prior written clearance n/a provided to allow the trade to proceed during this period? If prior written clearance was provided, n/a on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011